iPSC-Derived Organoid Differentiation Protocols
Materials Required
Principle
IPSC-derived organoid differentiation uses staged developmental signaling to guide pluripotent cells into lineage-specific progenitors, followed by three-dimensional self-organization into tissue-like structures. Classic examples include cerebral organoids formed through embryoid-body neural induction and 3D expansion, intestinal and gastric organoids formed through definitive endoderm and gut-patterning stages, kidney organoids formed through intermediate-mesoderm induction, lung organoids formed through definitive-endoderm, anterior-foregut, and ventral-lung patterning, and liver buds formed by combining iPSC-derived hepatic endoderm with endothelial and mesenchymal cells[1][2][3][4][5][6][7][8][9][10]. The readout is organoid morphology plus lineage-marker evidence, such as cortical neural progenitor and neuron organization in cerebral organoids, FOXA2/SOX17 definitive endoderm and CDX2 hindgut identity in intestinal differentiation, nephron and collecting-duct-associated structures in kidney organoids, foregut/lung epithelial markers in lung organoids, and hepatic-bud vascularization after transplantation in liver-bud experiments[1][2][3][4][5][6][7][8][9][10].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
• Use validated human iPSC lines maintained under pluripotent culture conditions; use lineage-specific media and growth-factor sequences reported for the target organoid type, including Activin A for definitive endoderm induction in intestinal, gastric, and lung protocols; WNT/FGF signaling for hindgut or foregut-patterning contexts; CHIR99021, FGF9, and heparin for kidney organoid induction; extracellular matrix embedding such as Matrigel for cerebral, intestinal, gastric, and lung organoid 3D culture where reported; and endothelial plus mesenchymal cell components for iPSC-derived liver-bud assembly[1][2][3][4][7][8][9][10].
• Use immunostaining or molecular assays for lineage validation rather than assuming differentiation from morphology alone; reported markers include FOXA2 and SOX17 for definitive endoderm, CDX2 for intestinal hindgut patterning, kidney lineage markers for segmented nephron structures, lung epithelial and mesenchymal markers for lung organoids, and neural progenitor/neuron markers for cerebral organoids[1][2][3][4][5][6][7][8][9].
• Use standard sterile cell-culture equipment, a CO2 incubator, low-adhesion cultureware or embryoid-body culture formats where specified, centrifugation equipment for kidney pellet aggregation where specified, extracellular-matrix droplet or embedding setups where specified, an orbital shaker or spinning bioreactor for cerebral organoid maturation where specified, and microscopy platforms for morphology and immunostaining readouts[1][2][4][7][8].
• Use immunostaining or molecular assays for lineage validation rather than assuming differentiation from morphology alone; reported markers include FOXA2 and SOX17 for definitive endoderm, CDX2 for intestinal hindgut patterning, kidney lineage markers for segmented nephron structures, lung epithelial and mesenchymal markers for lung organoids, and neural progenitor/neuron markers for cerebral organoids[1][2][3][4][5][6][7][8][9].
• Use standard sterile cell-culture equipment, a CO2 incubator, low-adhesion cultureware or embryoid-body culture formats where specified, centrifugation equipment for kidney pellet aggregation where specified, extracellular-matrix droplet or embedding setups where specified, an orbital shaker or spinning bioreactor for cerebral organoid maturation where specified, and microscopy platforms for morphology and immunostaining readouts[1][2][4][7][8].
Experimental Procedure
• Start with high-quality undifferentiated iPSCs and select one organoid lineage before beginning, because published protocols use different signaling sequences and timelines for cerebral, intestinal, kidney, gastric, lung, and liver-bud organoids[1][2][3][4][7][8][9][10].
• Prepare the differentiation media according to the chosen literature-supported lineage route: cerebral protocols begin with embryoid-body formation and neural induction; intestinal protocols induce definitive endoderm for 3 days before FGF4/WNT3A hindgut patterning; kidney protocols use approximately 7 days of monolayer differentiation followed by 3D aggregation and maturation; lung protocols generate definitive endoderm, anterior foregut, ventral-anterior foregut spheroids, and then lung organoids; gastric protocols manipulate FGF, WNT, BMP, retinoic-acid, and EGF signaling; liver-bud protocols combine iPSC-derived hepatic endoderm with endothelial and mesenchymal cells[1][2][4][7][8][9][10].
• For cerebral organoids, form embryoid bodies from human pluripotent stem cells, induce neuroectoderm, embed developing neuroepithelial tissues in extracellular matrix, and transfer organoids to long-term 3D culture with improved nutrient and oxygen exchange using spinning culture when following the Lancaster protocol[1].
• For intestinal organoids, induce FOXA2-positive/SOX17-positive definitive endoderm using Activin A for 3 days, pattern the endoderm toward CDX2-positive mid/hindgut tissue with FGF4 and WNT3A, collect emerging hindgut spheroids, and culture them in 3D extracellular matrix with intestinal growth conditions[2][3].
• For kidney organoids, induce intermediate mesoderm from hPSCs in monolayer culture using CHIR99021 followed by FGF9/heparin-based conditions, aggregate cells into 3D pellets at day 7, and continue 3D culture for approximately 11-18 additional days to generate organoids containing nephron-associated structures[4][5][6].
• For lung organoids, induce definitive endoderm, specify anterior foregut, ventralize foregut spheroids toward lung fate, and expand spheroids in 3D culture to form human lung organoids; the published Nature Protocols workflow reports human lung organoid generation over approximately 50-85 days and bud-tip progenitor organoids over approximately 22 days[7][8].
• For gastric organoids, generate definitive endoderm, pattern posterior foregut, and use temporal manipulation of FGF, WNT, BMP, retinoic-acid, and EGF signaling plus 3D growth to produce human gastric organoids resembling developing antral gastric tissue[9].
• For liver-bud organoids, differentiate iPSCs toward hepatic endoderm and assemble them with endothelial and mesenchymal cells to form liver-bud-like structures; functional vascularized tissue formation was demonstrated after transplantation in the original study rather than as a fully mature in vitro liver organoid endpoint[10].
• Assess organoid success using morphology, lineage-marker staining, and molecular assays appropriate to the selected lineage; do not score organoids as correctly differentiated from bright-field appearance alone when the original studies used marker expression and tissue organization as validation endpoints[1][2][3][4][5][6][7][8][9][10].
• Use positive controls when available, such as previously validated differentiating organoids or fetal/adult tissue marker references, and use negative controls such as undifferentiated iPSCs or omission of lineage-patterning factors where reported; kidney, intestinal, lung, gastric, and cerebral studies compared organoids against expected developmental marker patterns rather than relying only on survival or size[1][2][3][4][5][6][7][8][9].
• Prepare the differentiation media according to the chosen literature-supported lineage route: cerebral protocols begin with embryoid-body formation and neural induction; intestinal protocols induce definitive endoderm for 3 days before FGF4/WNT3A hindgut patterning; kidney protocols use approximately 7 days of monolayer differentiation followed by 3D aggregation and maturation; lung protocols generate definitive endoderm, anterior foregut, ventral-anterior foregut spheroids, and then lung organoids; gastric protocols manipulate FGF, WNT, BMP, retinoic-acid, and EGF signaling; liver-bud protocols combine iPSC-derived hepatic endoderm with endothelial and mesenchymal cells[1][2][4][7][8][9][10].
• For cerebral organoids, form embryoid bodies from human pluripotent stem cells, induce neuroectoderm, embed developing neuroepithelial tissues in extracellular matrix, and transfer organoids to long-term 3D culture with improved nutrient and oxygen exchange using spinning culture when following the Lancaster protocol[1].
• For intestinal organoids, induce FOXA2-positive/SOX17-positive definitive endoderm using Activin A for 3 days, pattern the endoderm toward CDX2-positive mid/hindgut tissue with FGF4 and WNT3A, collect emerging hindgut spheroids, and culture them in 3D extracellular matrix with intestinal growth conditions[2][3].
• For kidney organoids, induce intermediate mesoderm from hPSCs in monolayer culture using CHIR99021 followed by FGF9/heparin-based conditions, aggregate cells into 3D pellets at day 7, and continue 3D culture for approximately 11-18 additional days to generate organoids containing nephron-associated structures[4][5][6].
• For lung organoids, induce definitive endoderm, specify anterior foregut, ventralize foregut spheroids toward lung fate, and expand spheroids in 3D culture to form human lung organoids; the published Nature Protocols workflow reports human lung organoid generation over approximately 50-85 days and bud-tip progenitor organoids over approximately 22 days[7][8].
• For gastric organoids, generate definitive endoderm, pattern posterior foregut, and use temporal manipulation of FGF, WNT, BMP, retinoic-acid, and EGF signaling plus 3D growth to produce human gastric organoids resembling developing antral gastric tissue[9].
• For liver-bud organoids, differentiate iPSCs toward hepatic endoderm and assemble them with endothelial and mesenchymal cells to form liver-bud-like structures; functional vascularized tissue formation was demonstrated after transplantation in the original study rather than as a fully mature in vitro liver organoid endpoint[10].
• Assess organoid success using morphology, lineage-marker staining, and molecular assays appropriate to the selected lineage; do not score organoids as correctly differentiated from bright-field appearance alone when the original studies used marker expression and tissue organization as validation endpoints[1][2][3][4][5][6][7][8][9][10].
• Use positive controls when available, such as previously validated differentiating organoids or fetal/adult tissue marker references, and use negative controls such as undifferentiated iPSCs or omission of lineage-patterning factors where reported; kidney, intestinal, lung, gastric, and cerebral studies compared organoids against expected developmental marker patterns rather than relying only on survival or size[1][2][3][4][5][6][7][8][9].
Troubleshooting
Problem: Organoids show poor lineage identity.
• Possible cause: The differentiation sequence may not match the target lineage.• Literature-supported solution: Use only the staged signaling route validated for the intended organoid type, such as Activin A followed by FGF/WNT for intestinal endoderm-to-hindgut differentiation, CHIR99021 followed by FGF9/heparin for kidney organoids, or definitive-endoderm to anterior-foregut to ventral-lung patterning for lung organoids[2][3][4][7][8].
Problem: Kidney organoids lack expected nephron-associated organization.
• Possible cause: Intermediate-mesoderm induction or 3D aggregation timing may be incorrect.• Literature-supported solution: Follow the reported 7-day monolayer induction followed by 3D pellet culture for 11-18 days, and validate segmented nephron-associated structures with lineage markers[4][5][6].
Problem: Lung organoid cultures fail to produce lung-like spheroids.
• Possible cause: Foregut anteriorization or ventralization may be incomplete.• Literature-supported solution: Confirm definitive endoderm and anterior foregut stages before lung-patterning expansion, because the lung protocols build lung organoids through sequential developmental intermediates[7][8].
Problem: Cerebral organoids show limited growth in long-term culture.
• Possible cause: 3D tissues may have insufficient exchange of nutrients and oxygen.• Literature-supported solution: Use the reported extracellular-matrix embedding and spinning-culture workflow for cerebral organoid maturation[1].
References:
- [1]. Lancaster MA, et al. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014;9(10):2329-2340. [Content Brief]
- [2]. McCracken KW, et al. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat Protoc. 2011;6(12):1920-1928. [Content Brief]
- [3]. Spence JR, Mayhew CN, Rankin SA, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011;470(7332):105-109. [Content Brief]
- [4]. Takasato M, et al. Generation of kidney organoids from human pluripotent stem cells. Nat Protoc. 2016;11(9):1681-1692. [Content Brief]
- [5]. Takasato M, Er PX, Chiu HS, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015;526(7574):564-568. [Content Brief]
- [6]. Morizane R, et al. Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol. 2015;33(11):1193-1200. [Content Brief]
- [7]. Dye BR, Hill DR, Ferguson MA, et al. In vitro generation of human pluripotent stem cell derived lung organoids. Elife. 2015;4:e05098. [Content Brief]
- [8]. Miller AJ, Dye BR, Ferrer-Torres D, et al. Generation of lung organoids from human pluripotent stem cells in vitro. Nat Protoc. 2019;14(2):518-540. [Content Brief]
- [9]. McCracken KW, Catá EM, Crawford CM, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature. 2014;516(7531):400-404. [Content Brief]
- [10]. Takebe T, Sekine K, Enomura M, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481-484. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail